F18.251
Inhalant dependence with inhalant-induced psychotic disorder with hallucinations
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 Code F18.251 refers to a condition where an individual is dependent on inhalants and experiences an inhalant-induced psychotic disorder characterized by hallucinations. This condition highlights the serious mental health complications that can arise from the use of inhalants, substances often used recreationally for their psychoactive effects. Understanding this disorder involves exploring its causes, symptoms, diagnosis methods, and potential treatment options.
Causes & Symptoms
Clinical Causes: Prolonged or frequent use of inhalants such as solvents, aerosols, gases, or nitrites. Genetic predisposition that may increase vulnerability to substance dependence and psychosis. Environmental factors including peer pressure, availability of inhalants, and social influences. Underlying mental health conditions that may contribute to substance use as a form of self-medication. Lack of awareness or education about the dangers associated with inhalant use.
Key Symptoms: Visual or auditory hallucinations that can be frightening or confusing. Depressive moods or paranoid thoughts occurring during or after inhalant use. Disorganized thinking or confusion. Mood swings or agitation. Physical signs such as dizziness, lack of coordination, or chemical odors on breath or clothing. Behavioral changes including withdrawal from activities or social isolation. Memory problems or difficulty concentrating.
Diagnostic & Treatment
Diagnosis Path: Diagnosing inhalant dependence with psychosis involves a combination of medical history assessment, clinical observation, and sometimes laboratory tests. Healthcare professionals typically evaluate the patient's history of inhalant use, look for physical or mental signs of substance dependence, and consider the presence of psychotic symptoms such as hallucinations. Mental health assessments may include standardized questionnaires or interviews to gauge the severity of symptoms and their impact on daily functioning.
Treatment Protocols: Detoxification and cessation support to safely manage withdrawal symptoms. Psychotherapy options such as cognitive-behavioral therapy (CBT) to modify harmful thought patterns and behaviors. Medications to help stabilize mood and reduce psychotic symptoms, as prescribed by a healthcare professional. Support groups or outpatient programs for ongoing education, coping skills, and peer support. Addressing underlying mental health issues that may contribute to substance dependence. Family therapy or counseling to improve support systems and communication.
Clinical Advice & FAQs
Billing Guidance
Is F18.251 a billable ICD-10 code?
Yes, F18.251 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.251?
Clinical documentation must specify the nature of Inhalant dependence with inhalant-induced psychotic disorder with hallucinations and any associated comorbidities for accurate reporting.
Cite this Clinical Reference